On Tuesday, CRISPR Therapeutics AG (NASDAQ: CRSP) opened lower -4.42% from the last session, before settling in for the closing price of $46.57. Price fluctuations for CRSP have ranged from $36.52 to $90.62 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 31550.17%. Company’s average yearly earnings per share was noted -9.69% at the time writing. With a float of $82.08 million, this company’s outstanding shares have now reached $85.74 million.
Let’s determine the extent of company efficiency that accounts for 393 employees. In terms of profitability, gross margin is -227.47%, operating margin of -1273.97%, and the pretax margin is -990.27%.
CRISPR Therapeutics AG (CRSP) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CRISPR Therapeutics AG is 4.31%, while institutional ownership is 69.42%. The most recent insider transaction that took place on Feb 19 ’25, was worth 1,013,564. In this transaction Chief Executive Officer of this company sold 18,360 shares at a rate of $55.20, taking the stock ownership to the 171,613 shares. Before that another transaction happened on Feb 18 ’25, when Company’s Chief Executive Officer sold 11,640 for $55.05, making the entire transaction worth $640,782. This insider now owns 196,901 shares in total.
CRISPR Therapeutics AG (CRSP) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.69% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Check out the current performance indicators for CRISPR Therapeutics AG (CRSP). In the past quarter, the stock posted a quick ratio of 22.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 102.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.36, a number that is poised to hit -1.23 in the next quarter and is forecasted to reach -3.92 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Looking closely at CRISPR Therapeutics AG (NASDAQ: CRSP), its last 5-days average volume was 2.96 million, which is a jump from its year-to-date volume of 2.42 million. As of the previous 9 days, the stock’s Stochastic %D was 42.63%. Additionally, its Average True Range was 3.01.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 35.43%, which indicates a significant increase from 35.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.39% in the past 14 days, which was higher than the 57.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $42.57, while its 200-day Moving Average is $49.35. However, in the short run, CRISPR Therapeutics AG’s stock first resistance to watch stands at $46.11. Second resistance stands at $47.72. The third major resistance level sits at $48.76. If the price goes on to break the first support level at $43.46, it is likely to go to the next support level at $42.42. Now, if the price goes above the second support level, the third support stands at $40.81.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
There are currently 85,774K shares outstanding in the company with a market cap of 3.82 billion. Presently, the company’s annual sales total 37,310 K according to its annual income of -366,250 K. Last quarter, the company’s sales amounted to 35,690 K and its income totaled -37,310 K.
